Product Description
VPJ neither forms nor acts like an epicutaneous impermeable membrane; instead, it permeates throughout the SC interstices, allowing normal barrier recovery despite its occlusive properties. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1564142/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Topical,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Lebanon | Malaysia | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | South Africa | Spain | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|